Vildagliptine protects SH-SY5Y human neuron-like cells from Aβ 1–42 induced toxicity, in vitro

The amyloid β (A β ) toxic fibrils is thought to play a central role in the onset and progression of Alzheimer’s disease (AD) because of it is a main formation of senile plaques. Diabetic patients are more vulnerable to caught Alzheimer’s disease. Vildagliptine, a novel anti diabetic agent, has been reported to exert protective effects on AD rat models in restricted study. We aimed to investigate any protective effects of vildagliptine against A β fibrils on SH-SY5Y cell line. Vildagliptine decreased PSEN1 and PSEN2 mRNA levels which enroll A β production. In addition, vildagliptin was downregulated caspase-3 and caspase-9 expression levels which were evoked by A β . Also we confirmed cellular viability with real time cell analyzer and MTT assay. Our data exposed that vildagliptine has lowering effect on GSK3 β and Tau phosphorylation. However we did not get protective effect of vildagliptine against A β toxicity on mitochondrial membrane potential. These results indicate that vildagliptine exerts a protective effect against A β by decreasing apoptosis related proteins, lowering GSK3 β and Tau phosphorylation levels in addition to expression of PSEN1 and PSEN2 mRNA downregulation effect.